Vyliq, formerly known as relecabtagene autotempa, represents a groundbreaking step in the treatment of relapsed or refractory aggressive large B-cell lymphoma (LBCL). This distinct intervention utilizes a altered CAR-T https://vyliq628637.activoblog.com/598004/vyliq-a-deep-look-into-the-new-treatment